SAN DIEGO, June 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- BioMed Realty Trust, Inc.
(NYSE: BMR) announced today that its underwriters have exercised their over-
allotment option in full to purchase an additional 1,972,500 shares of common
stock to be offered at the public offering price of $22.50 per share, all of
which are being sold by the company. In total, the company sold 15,122,500
shares of common stock, which will raise gross offering proceeds of
Raymond James & Associates Inc. acted as the sole lead book-running
manager, with KeyBanc Capital Markets, Wachovia Capital Markets LLC, Friedman
Billings Ramsey & Co. Inc., Legg Mason Wood Walker Inc. and RBC Capital
Markets Corp. acting as co-managers of the offering.
The offering of these securities is made only by means of a prospectus,
copies of which may be obtained by contacting Raymond James & Associates,
Inc., 880 Carillon Parkway, St. Petersburg, FL 33716.
The registration statement relating to these securities has been declared
effective by the Securities and Exchange Commission. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of such securities in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused
on acquiring, developing, owning, leasing and managing laboratory and office
space for the life science industry. Our tenants include biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. Additional
information is available at http://www.biomedrealty.com .
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: the company's ability to
close this public offering on the terms described in this release, or at all,
and if this offering closes, the level of the company's share price, which may
decline; general risks affecting the real estate industry (including, without
limitation, the inability to enter into or renew leases, dependence on
tenants' financial condition, and competition from other developers, owners
and operators of real estate); adverse economic or real estate developments in
the life science industry or the Boston or California regions; risks
associated with the availability and terms of financing and the use of debt to
fund acquisitions and developments; failure to manage effectively the
company's growth and expansion into new markets, or to complete or integrate
acquisitions successfully; risks and uncertainties affecting property
development and construction; risks associated with downturns in the national
and local economies, increases in interest rates, and volatility in the
securities markets; potential liability for uninsured losses and environmental
contamination; risks associated with the company's potential failure to
qualify as a REIT under the Internal Revenue Code of 1986, as amended, and
possible adverse changes in tax and environmental laws; and risks associated
with the company's dependence on key personnel whose continued service is not
guaranteed. For a further list and description of such risks and
uncertainties, see the reports filed by the company with the Securities and
Exchange Commission, including the company's most recent annual report on Form
10-K. The company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE BioMed Realty Trust, Inc.
John F. Wilson, II, Chief Financial Officer, BioMed Realty Trust, +1-858-485-9840